scholarly journals Identification of Lifestyle Behaviors Associated with Recurrence and Survival in Colorectal Cancer Patients Using Random Survival Forests

Cancers ◽  
2021 ◽  
Vol 13 (10) ◽  
pp. 2442
Author(s):  
Moniek van Zutphen ◽  
Fränzel J. B. van Duijnhoven ◽  
Evertine Wesselink ◽  
Ruud W. M. Schrauwen ◽  
Ewout A. Kouwenhoven ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Recurrence Risk ◽  
Lifestyle Behaviors ◽  
Sugary Drinks ◽  
All Cause Mortality ◽  
Random Survival Forests ◽  
Colorectal Cancer Patients ◽  
Survival Forests ◽  
Risk Of Cancer

Current lifestyle recommendations for cancer survivors are the same as those for the general public to decrease their risk of cancer. However, it is unclear which lifestyle behaviors are most important for prognosis. We aimed to identify which lifestyle behaviors were most important regarding colorectal cancer (CRC) recurrence and all-cause mortality with a data-driven method. The study consisted of 1180 newly diagnosed stage I–III CRC patients from a prospective cohort study. Lifestyle behaviors included in the current recommendations, as well as additional lifestyle behaviors related to diet, physical activity, adiposity, alcohol use, and smoking were assessed six months after diagnosis. These behaviors were simultaneously analyzed as potential predictors of recurrence or all-cause mortality with Random Survival Forests (RSFs). We observed 148 recurrences during 2.6-year median follow-up and 152 deaths during 4.8-year median follow-up. Higher intakes of sugary drinks were associated with increased recurrence risk. For all-cause mortality, fruit and vegetable, liquid fat and oil, and animal protein intake were identified as the most important lifestyle behaviors. These behaviors showed non-linear associations with all-cause mortality. Our exploratory RSF findings give new ideas on potential associations between certain lifestyle behaviors and CRC prognosis that still need to be confirmed in other cohorts of CRC survivors.

scholarly journals Targeted Plasma Metabolic Profiles and Risk of Recurrence in Stage II and III Colorectal Cancer Patients: Results from an International Cohort Consortium

Metabolites ◽  
2021 ◽  
Vol 11 (3) ◽  
pp. 129
Author(s):  
Jennifer Ose ◽  
Biljana Gigic ◽  
Stefanie Brezina ◽  
Tengda Lin ◽  
Andreas Baierl ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Multiple Testing ◽  
Tumor Stage ◽  
Stage Ii ◽  
Sphingolipid Metabolism ◽  
Risk Of Recurrence ◽  
Cox Proportional Hazard Models ◽  
Edta Plasma ◽  
Colorectal Cancer Patients

The identification of patients at high-risk for colorectal cancer (CRC) recurrence remains an unmet clinical need. The aim of this study was to investigate associations of metabolites with risk of recurrence in stage II/III CRC patients. A targeted metabolomics assay (128 metabolites measured) was performed on pre-surgery collected EDTA plasma samples from n = 440 newly diagnosed stage II/III CRC patients. Patients have been recruited from four prospective cohort studies as part of an international consortium: Metabolomic profiles throughout the continuum of CRC (MetaboCCC). Cox proportional hazard models were computed to investigate associations of metabolites with recurrence, adjusted for age, sex, tumor stage, tumor site, body mass index, and cohort; false discovery rate (FDR) was used to account for multiple testing. Sixty-nine patients (15%) had a recurrence after a median follow-up time of 20 months. We identified 13 metabolites that were nominally associated with a reduced risk of recurrence. None of the associations were statistically significant after controlling for multiple testing. Pathway topology analyses did not reveal statistically significant associations between recurrence and alterations in metabolic pathways (e.g., sphingolipid metabolism p = 0.04; pFDR = 1.00). To conclude, we did not observe statistically significant associations between metabolites and CRC recurrence using a well-established metabolomics assay. The observed results require follow-up in larger studies.

Development and implementation of a remote follow-up plan for colorectal cancer patients

2020 ◽  
Vol 46 (3) ◽  
pp. 429-432 ◽  
Author(s):  
S.M. Qaderi ◽  
H. Vromen ◽  
H.M. Dekker ◽  
M.W.J. Stommel ◽  
A.J.A. Bremers ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Cancer Patients ◽  
Colorectal Cancer Patients

scholarly journals Chemotherapy and target therapy as neo-adjuvant approach for initially unresectable colorectal liver metastases

2012 ◽  
Vol 6 (1) ◽  
pp. 6
Author(s):  
Luigi Rossi ◽  
Angelo Zullo ◽  
Federica Zoratto ◽  
Anselmo Papa ◽  
Martina Strudel ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Liver Metastases ◽  
Cancer Patients ◽  
Target Therapy ◽  
Resection Rate ◽  
Biological Drugs ◽  
Unresectable Colorectal Liver Metastases ◽  
Neo Adjuvant Chemotherapy ◽  
Colorectal Cancer Patients

Although surgery is the most effective treatment for liver metastases in colorectal cancer patients, only 15-20% of these patients are suitable for a radical surgical approach, and metastases recurrence may occur at follow up. In the last decade, the use of pre-operative chemotherapy in combination with new biological drugs has been introduced. We reviewed data of neo-adjuvant chemotherapy strategies aimed at increasing the resection rate of liver metastases in colorectal cancer patients who were initially considered unresectable.

Initiation and Discontinuation of Complementary Therapy Among Cancer Patients

2007 ◽  
Vol 25 (33) ◽  
pp. 5267-5274 ◽  
Author(s):  
Sung-Gyeong Kim ◽  
Eun-Cheol Park ◽  
Jae-Hyun Park ◽  
Myung-Il Hahm ◽  
Jin-Hwa Lim ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Cancer Patients ◽  
Initial Treatment ◽  
Stage Iv ◽  
Complementary Therapy ◽  
Cancer Center ◽  
Cumulative Probability ◽  
Colorectal Cancer Patients ◽  
The Impact

PurposeTo identify the initiation or discontinuation of complementary therapy (CT) and determine the impact of sociodemographic and clinical factors on CT use among cancer patients.Patients and MethodsEligible patients were age 20 or older; newly diagnosed with stomach, liver, or colorectal cancer; and started their initial treatment at the National Cancer Center, Korea, between April 1, 2001, and April 30, 2003. In total, 541 cancer patients were surveyed in face-to-face interviews at baseline, and telephone follow-up interviews were performed every 3 months for 3 years.ResultsA total of 281 patients commenced CT after diagnosis; 164 patients stopped using CT during the follow-up period. The overall cumulative probability of starting CT at 1, 2, and 3 years was 50%, 54%, and 55%, respectively. In a Cox multivariate analysis, stomach and liver cancer were associated with an increased probability of initiating CT compared with colorectal cancer. Patients who were classified as stage I, II, or III at diagnosis were associated with a decreased probability of discontinuing CT compared with stage IV.ConclusionMost cancer patients started to use CT during the initial treatment period. Thus, physicians should communicate with cancer patients about CT at this phase. In particular, more attention should be paid to women and individuals with higher household incomes because these groups are more likely to start CT.

scholarly journals Clinical–pathological characteristics and short-term follow-up associated with proliferation, apoptosis and angiogenesis in a prospective cohort of patients with colorectal tumours

Tumor Biology ◽  
2019 ◽  
Vol 41 (4) ◽  
pp. 101042831983568
Author(s):  
Maximino Redondo ◽  
Cristina Abitei ◽  
Teresa Téllez ◽  
Rafael Fúnez ◽  
Teresa Pereda ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Prospective Cohort ◽  
Good Prognosis ◽  
Terminal Deoxynucleotidyl Transferase ◽  
Short Term ◽  
Ki 67 ◽  
Term Survival ◽  
Colorectal Tumour ◽  
Colorectal Cancer Patients

We investigate the clinical and pathological features related to variations in colorectal tumour apoptosis, proliferation and angiogenesis and the influence of the latter in short-term mortality (2 years); 551 tumour samples from a prospective cohort of patients with colorectal cancer were examined and tumour biology markers were determined as follows: percentage of apoptotic cells, by the terminal deoxynucleotidyl transferase (TdT) dUTP Nick-End Labeling technique; Ki-67 antigen, as a cell proliferation marker and density of microvessels (as a marker of angiogenesis). An increase in the percentage of cellular apoptosis is significantly related to the presence of poorly differentiated tumours, with vascular invasion (p < 0.001). The CD105 angiogenesis marker is not related to any clinical–pathological parameter except that of higher frequency in older patients (p = 0.03). Ki-67 is more frequently expressed in tumours with less nervous invasion (p = 0.05). Neither apoptosis nor angiogenesis present any significant association with short-term survival. The only marker clearly related to 2-year survival is Ki-67, which is shown to be a good prognostic factor in the multivariate analysis (hazard ratio = 0.49; 95% confidence interval = 0.27–0.90). Therefore, in a prospective cohort of colorectal cancer patients, only Ki-67 is a marker of good prognosis in short-term follow-up.

Standardization, specificity, and diagnostic sensitivity of four immunoassays for carcinoembryonic antigen

1991 ◽  
Vol 37 (2) ◽  
pp. 231-236 ◽  
Author(s):  
Ole P Börmer
Keyword(s):  
Colorectal Cancer ◽  
Monoclonal Antibodies ◽  
Carcinoembryonic Antigen ◽  
Normal Values ◽  
The Other ◽  
Reference Limit ◽  
Sandwich Type ◽  
Reference Preparation ◽  
Colorectal Cancer Patients

Abstract Four "sandwich"-type immunoassays for carcinoembryonic antigen (CEA) based on monoclonal antibodies (Abbott CEA-RIA Monoclonal, Pharmacia/Wallac Delfia CEA kit, Roche CEA EIA Duomab 60, and our in-house immunoradiometric assay) were compared for 357 samples from colorectal cancer patients and samples from 48 patients with chronic liver disease or with acute, irrelevant diseases. Relative to a common 5 micrograms/L reference limit, all four assays agreed regarding classification in 92% to 94% of the samples in the colorectal cancer samples, with the Abbott and Roche assays giving slightly more "normal" values. Cross-testing of CEA standards and the 1st International Reference Preparation 73/601 showed that calibration differences could not be eliminated by the use of a common standard. It has been earlier demonstrated that the monoclonal antibodies in the Roche assay have an epitope group specificity slightly different from those of the other three assays. This can explain why the correlations involving the Roche assay were weaker (r = 0.84-0.87) than those obtained with the other assays (r = 0.94-0.97). I conclude that agreement between the assays studied is as good as can be expected when different antibodies are used; nevertheless, consistent discrepancies between assays in several patients still necessitate the use of the same assay during follow-up.

Leukocyte Adherence Inhibition Assay in the Diagnosis and Follow-Up of Colorectal Cancer Patients

Oncology ◽  
1986 ◽  
Vol 43 (1) ◽  
pp. 23-26 ◽  
Author(s):  
Z. Weisman ◽  
A. Shani ◽  
A. Fink ◽  
A. Shindel ◽  
A. Sela ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Cancer Patients ◽  
Leukocyte Adherence ◽  
Inhibition Assay ◽  
Leukocyte Adherence Inhibition ◽  
Colorectal Cancer Patients ◽  
Adherence Inhibition

scholarly journals Frequency of replication errors in colorectal cancer and their association with family history

Gut ◽  
1998 ◽  
Vol 43 (4) ◽  
pp. 553-557 ◽  
Author(s):  
S R Brown ◽  
P J Finan ◽  
L Cawkwell ◽  
P Quirke ◽  
D T Bishop
Keyword(s):  
Colorectal Cancer ◽  
Family History ◽  
Mutation Status ◽  
Replication Errors ◽  
Cancer Group ◽  
Amsterdam Criteria ◽  
History Of ◽  
Regional Population ◽  
Colorectal Cancer Patients

Background—Replication errors (RERs) characterise tumours of hereditary non-polyposis colorectal cancer (HNPCC). RER status may therefore improve identification of such families previously diagnosed by family history alone.Aims—To assess RER and HNPCC frequency within a population of colorectal cancer patients and a regional population of family history defined (Amsterdam criteria) HNPCC families.Methods—Family history was assessed by personal interview in a population of 479 patients with colorectal cancer attending one follow up clinic. Seven fluorescently labelled microsatellites were used to investigate RER frequency in colorectal cancers from 89 patients of this population with varying degrees of family history and 20 Amsterdam criteria positive families (four with a known germline mutation, 16 with unknown mutation status) from the regional population.Results—Only four of the follow up population (0.8%) came from families meeting the Amsterdam criteria with only one showing RERs. The frequency of RERs was similar in the early onset cancer group (less than 50 years of age), those with a family history, and those with no family history of colorectal cancer. From the regional population, RERs were identified in 4/4 families with a mutation but only 8/16 families with unknown mutation status.Conclusions—No correlation was seen between RER status and strength of family history except in HNPCC families. Results also indicate that half of the Amsterdam criteria defined families do not exhibit RERs, perhaps suggesting a different mechanism of tumorigenesis.

Sign in / Sign up

Export Citation Format

Share Document